Headshot of John W. Krakauer.

John W. Krakauer

Director of the Centre for Restorative Neurotechnology, Champalimaud Foundation
Professor of neurology, Johns Hopkins University

John Krakauer is director of the Centre for Restorative Neurotechnology at the Champalimaud Foundation and John C. Malone professor of neurology, neuroscience, and physical medicine and rehabilitation at Johns Hopkins University. He is also an external professor at the Santa Fe Institute. Krakauer is a world leader in motor control and stroke recovery, and his work bridges the gap between basic neuroscience, creative engineering and the philosophy of mind. At the Champalimaud Foundation, he leads the “software as medicine” initiative, using immersive animation, generative artificial intelligence and digital neurotherapeutics to treat chronic neurological and psychiatric conditions. 

He is co-inventor of the “MindPod Dolphin,” an FDA-listed neuro-rehabilitation technology licensed to MindMaze. He is also the author of “Broken Movement: The Neurobiology of Motor Recovery after Stroke” (MIT Press) and is currently writing a new book on the nature of intelligence for Princeton University Press. His research and unique approach to “exergaming” for brain health have been profiled in The New Yorker, The Atlantic and The New York Times.

Explore more from The Transmitter

Headshots of Yale researchers Yong-Hui Jiang and Jiangbing Zhou.

Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions

Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.

By Natalia Mesa
3 June 2026 | 11 min read

What counts as a ‘naturalistic’ behavior?

Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.

By Paul Middlebrooks
3 June 2026 | 1 min read
Research image of brain cells involved with Amyotrophic lateral sclerosis (ALS) illuminated through genetic tools

Allen Institute sets sights on treatments for five brain diseases

The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.

By Calli McMurray
2 June 2026 | 5 min read